Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Koichiro Maie, Yasuhisa Yokoyama, Naoki Kurita, Hideto Minohara, Shintaro Yanagimoto, Yuichi Hasegawa, Masato Homma, Shigeru Chiba

ABSTRACT

PURPOSE: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for prevention of hyperuricemia associated with tumor lysis syndrome (TLS). METHODS: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat within 7 days before initiation of chemotherapy were retrieved retrospectively at a single institute. The changes in serum uric acid levels from before and 7 days after initiation of febuxostat were evaluated and compared with the historical control group of patients who received allopurinol. We also evaluated non-hematological adverse events during the study period. RESULTS: A total of 78 patients' records were analyzed, 38 in the febuxostat group and 39 in the allopurinol group. There were no significant differences in the incidence of treatment failure, defined as development of clinical TLS or receiving rasburicase, between the febuxostat and allopurinol group (5.2% vs 5.1%, P>0.99). The mean serum uric acid levels were significantly decreased, compared to the baseline (5.6 ± 2.1 mg/dL), at 7 days after initiation of febuxostat (3.1 ± 1.5 mg/dL, last observation carried forward, P<0.001). There were no statistically significant differences in the percent change in the serum uric acid levels between the 40 mg/day febuxostat and the 300 mg/day allopurinol groups (P = 0.57). Grade 3-4 liver dysfunctions were observed in both the febuxostat and allopurinol groups, without significant differences in incidence between the two groups (2.6% vs 5.1%, P>0.99). Neither gout flare nor skin rash occurred in any patients. CONCLUSIONS: Febuxostat is feasible for prevention of hyperuricemia associated with TLS. More... »

PAGES

501

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/2193-1801-3-501

DOI

http://dx.doi.org/10.1186/2193-1801-3-501

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042700701

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25279293


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maie", 
        "givenName": "Koichiro", 
        "id": "sg:person.0737713220.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737713220.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokoyama", 
        "givenName": "Yasuhisa", 
        "id": "sg:person.01130015361.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130015361.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurita", 
        "givenName": "Naoki", 
        "id": "sg:person.0644544347.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644544347.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Pharmaceutical Sciences, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Minohara", 
        "givenName": "Hideto", 
        "id": "sg:person.01275435004.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275435004.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Division for Health Service Promotion, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yanagimoto", 
        "givenName": "Shintaro", 
        "id": "sg:person.01040641267.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040641267.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hasegawa", 
        "givenName": "Yuichi", 
        "id": "sg:person.016316727112.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016316727112.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Pharmaceutical Sciences, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Homma", 
        "givenName": "Masato", 
        "id": "sg:person.0745126147.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745126147.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tsukuba", 
          "id": "https://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiba", 
        "givenName": "Shigeru", 
        "id": "sg:person.0671177613.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671177613.83"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/rhu.0b013e31821d352f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004575809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/rhu.0b013e31821d352f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004575809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2012.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028358194", 
          "https://doi.org/10.1038/bmt.2012.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1965.03090010007001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032611893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00045391-200501000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034132256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00045391-200501000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034132256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2010.08143.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034590894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2010.08143.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034590894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40264-013-0084-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043141260", 
          "https://doi.org/10.1007/s40264-013-0084-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2003.09.045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043662327"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-011-0041-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046256522", 
          "https://doi.org/10.1007/s12325-011-0041-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.0177", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050798832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077257675", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082233429", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "PURPOSE: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for prevention of hyperuricemia associated with tumor lysis syndrome (TLS).\nMETHODS: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat within 7\u00a0days before initiation of chemotherapy were retrieved retrospectively at a single institute. The changes in serum uric acid levels from before and 7\u00a0days after initiation of febuxostat were evaluated and compared with the historical control group of patients who received allopurinol. We also evaluated non-hematological adverse events during the study period.\nRESULTS: A total of 78 patients' records were analyzed, 38 in the febuxostat group and 39 in the allopurinol group. There were no significant differences in the incidence of treatment failure, defined as development of clinical TLS or receiving rasburicase, between the febuxostat and allopurinol group (5.2% vs 5.1%, P>0.99). The mean serum uric acid levels were significantly decreased, compared to the baseline (5.6 \u00b1 2.1\u00a0mg/dL), at 7\u00a0days after initiation of febuxostat (3.1 \u00b1 1.5\u00a0mg/dL, last observation carried forward, P<0.001). There were no statistically significant differences in the percent change in the serum uric acid levels between the 40\u00a0mg/day febuxostat and the 300\u00a0mg/day allopurinol groups (P\u2009=\u20090.57). Grade 3-4 liver dysfunctions were observed in both the febuxostat and allopurinol groups, without significant differences in incidence between the two groups (2.6% vs 5.1%, P>0.99). Neither gout flare nor skin rash occurred in any patients.\nCONCLUSIONS: Febuxostat is feasible for prevention of hyperuricemia associated with TLS.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/2193-1801-3-501", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1047790", 
        "issn": [
          "2193-1801"
        ], 
        "name": "SpringerPlus", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "3"
      }
    ], 
    "name": "Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome", 
    "pagination": "501", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cb66a3c8b7bd6c188369987ce473648fe1f1e01be552396e5cde00f5c9a4f2f0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25279293"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101597967"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/2193-1801-3-501"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042700701"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/2193-1801-3-501", 
      "https://app.dimensions.ai/details/publication/pub.1042700701"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F2193-1801-3-501"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/2193-1801-3-501'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/2193-1801-3-501'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/2193-1801-3-501'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/2193-1801-3-501'


 

This table displays all metadata directly associated to this object as RDF triples.

155 TRIPLES      21 PREDICATES      40 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/2193-1801-3-501 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N53d2e84ad0024ebea61b5e213056abc3
4 schema:citation sg:pub.10.1007/s12325-011-0041-1
5 sg:pub.10.1007/s40264-013-0084-0
6 sg:pub.10.1038/bmt.2012.244
7 https://app.dimensions.ai/details/publication/pub.1077257675
8 https://app.dimensions.ai/details/publication/pub.1082233429
9 https://doi.org/10.1001/jama.1965.03090010007001
10 https://doi.org/10.1016/j.amjmed.2003.09.045
11 https://doi.org/10.1097/00045391-200501000-00005
12 https://doi.org/10.1097/rhu.0b013e31821d352f
13 https://doi.org/10.1111/j.1365-2141.2010.08143.x
14 https://doi.org/10.1200/jco.2007.15.0177
15 schema:datePublished 2014-12
16 schema:datePublishedReg 2014-12-01
17 schema:description PURPOSE: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for prevention of hyperuricemia associated with tumor lysis syndrome (TLS). METHODS: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat within 7 days before initiation of chemotherapy were retrieved retrospectively at a single institute. The changes in serum uric acid levels from before and 7 days after initiation of febuxostat were evaluated and compared with the historical control group of patients who received allopurinol. We also evaluated non-hematological adverse events during the study period. RESULTS: A total of 78 patients' records were analyzed, 38 in the febuxostat group and 39 in the allopurinol group. There were no significant differences in the incidence of treatment failure, defined as development of clinical TLS or receiving rasburicase, between the febuxostat and allopurinol group (5.2% vs 5.1%, P>0.99). The mean serum uric acid levels were significantly decreased, compared to the baseline (5.6 ± 2.1 mg/dL), at 7 days after initiation of febuxostat (3.1 ± 1.5 mg/dL, last observation carried forward, P<0.001). There were no statistically significant differences in the percent change in the serum uric acid levels between the 40 mg/day febuxostat and the 300 mg/day allopurinol groups (P = 0.57). Grade 3-4 liver dysfunctions were observed in both the febuxostat and allopurinol groups, without significant differences in incidence between the two groups (2.6% vs 5.1%, P>0.99). Neither gout flare nor skin rash occurred in any patients. CONCLUSIONS: Febuxostat is feasible for prevention of hyperuricemia associated with TLS.
18 schema:genre research_article
19 schema:inLanguage en
20 schema:isAccessibleForFree true
21 schema:isPartOf N33adc3c04d0945499b6a4858180e9af1
22 Nd59e8893d3cc4bfe833723234e404031
23 sg:journal.1047790
24 schema:name Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
25 schema:pagination 501
26 schema:productId N118bdbcac74a467299406a26126276d1
27 N14677c0173b64532b020fb7bd5484510
28 N84ec95d607d94d92aa55368d23793ef5
29 Ne1b4b97011f04505acdb3a8a3afbbc0b
30 Ne4a5ac9f66894333a0405fc758dd6b40
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042700701
32 https://doi.org/10.1186/2193-1801-3-501
33 schema:sdDatePublished 2019-04-10T14:10
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N6d2c17e9acc546e38610990a2c8d6932
36 schema:url http://link.springer.com/10.1186%2F2193-1801-3-501
37 sgo:license sg:explorer/license/
38 sgo:sdDataset articles
39 rdf:type schema:ScholarlyArticle
40 N118bdbcac74a467299406a26126276d1 schema:name dimensions_id
41 schema:value pub.1042700701
42 rdf:type schema:PropertyValue
43 N14677c0173b64532b020fb7bd5484510 schema:name doi
44 schema:value 10.1186/2193-1801-3-501
45 rdf:type schema:PropertyValue
46 N27a03731044e4048a89f9a6f7527879c rdf:first sg:person.01040641267.33
47 rdf:rest N29c271e0b532430991642e9d4e399432
48 N29c271e0b532430991642e9d4e399432 rdf:first sg:person.016316727112.82
49 rdf:rest Na0b7a157e7a549d7a2950bce485b99d7
50 N2fc14dc9b8a947c885b2880186976ff6 rdf:first sg:person.0671177613.83
51 rdf:rest rdf:nil
52 N33adc3c04d0945499b6a4858180e9af1 schema:volumeNumber 3
53 rdf:type schema:PublicationVolume
54 N53d2e84ad0024ebea61b5e213056abc3 rdf:first sg:person.0737713220.33
55 rdf:rest Nabd669153d764f6aa2986a21ef9d554f
56 N6d2c17e9acc546e38610990a2c8d6932 schema:name Springer Nature - SN SciGraph project
57 rdf:type schema:Organization
58 N7e2140a5ab994e53bcf9da74c0f5d419 rdf:first sg:person.01275435004.92
59 rdf:rest N27a03731044e4048a89f9a6f7527879c
60 N84ec95d607d94d92aa55368d23793ef5 schema:name readcube_id
61 schema:value cb66a3c8b7bd6c188369987ce473648fe1f1e01be552396e5cde00f5c9a4f2f0
62 rdf:type schema:PropertyValue
63 Na0b7a157e7a549d7a2950bce485b99d7 rdf:first sg:person.0745126147.55
64 rdf:rest N2fc14dc9b8a947c885b2880186976ff6
65 Nabd669153d764f6aa2986a21ef9d554f rdf:first sg:person.01130015361.78
66 rdf:rest Nc6525602e429461faad5335dc2fe4517
67 Nc6525602e429461faad5335dc2fe4517 rdf:first sg:person.0644544347.48
68 rdf:rest N7e2140a5ab994e53bcf9da74c0f5d419
69 Nd59e8893d3cc4bfe833723234e404031 schema:issueNumber 1
70 rdf:type schema:PublicationIssue
71 Ne1b4b97011f04505acdb3a8a3afbbc0b schema:name nlm_unique_id
72 schema:value 101597967
73 rdf:type schema:PropertyValue
74 Ne4a5ac9f66894333a0405fc758dd6b40 schema:name pubmed_id
75 schema:value 25279293
76 rdf:type schema:PropertyValue
77 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
78 schema:name Medical and Health Sciences
79 rdf:type schema:DefinedTerm
80 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
81 schema:name Clinical Sciences
82 rdf:type schema:DefinedTerm
83 sg:journal.1047790 schema:issn 2193-1801
84 schema:name SpringerPlus
85 rdf:type schema:Periodical
86 sg:person.01040641267.33 schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
87 schema:familyName Yanagimoto
88 schema:givenName Shintaro
89 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040641267.33
90 rdf:type schema:Person
91 sg:person.01130015361.78 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
92 schema:familyName Yokoyama
93 schema:givenName Yasuhisa
94 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130015361.78
95 rdf:type schema:Person
96 sg:person.01275435004.92 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
97 schema:familyName Minohara
98 schema:givenName Hideto
99 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275435004.92
100 rdf:type schema:Person
101 sg:person.016316727112.82 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
102 schema:familyName Hasegawa
103 schema:givenName Yuichi
104 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016316727112.82
105 rdf:type schema:Person
106 sg:person.0644544347.48 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
107 schema:familyName Kurita
108 schema:givenName Naoki
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644544347.48
110 rdf:type schema:Person
111 sg:person.0671177613.83 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
112 schema:familyName Chiba
113 schema:givenName Shigeru
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671177613.83
115 rdf:type schema:Person
116 sg:person.0737713220.33 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
117 schema:familyName Maie
118 schema:givenName Koichiro
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737713220.33
120 rdf:type schema:Person
121 sg:person.0745126147.55 schema:affiliation https://www.grid.ac/institutes/grid.20515.33
122 schema:familyName Homma
123 schema:givenName Masato
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745126147.55
125 rdf:type schema:Person
126 sg:pub.10.1007/s12325-011-0041-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046256522
127 https://doi.org/10.1007/s12325-011-0041-1
128 rdf:type schema:CreativeWork
129 sg:pub.10.1007/s40264-013-0084-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043141260
130 https://doi.org/10.1007/s40264-013-0084-0
131 rdf:type schema:CreativeWork
132 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
133 https://doi.org/10.1038/bmt.2012.244
134 rdf:type schema:CreativeWork
135 https://app.dimensions.ai/details/publication/pub.1077257675 schema:CreativeWork
136 https://app.dimensions.ai/details/publication/pub.1082233429 schema:CreativeWork
137 https://doi.org/10.1001/jama.1965.03090010007001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032611893
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/j.amjmed.2003.09.045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043662327
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1097/00045391-200501000-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034132256
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1097/rhu.0b013e31821d352f schema:sameAs https://app.dimensions.ai/details/publication/pub.1004575809
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1111/j.1365-2141.2010.08143.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034590894
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1200/jco.2007.15.0177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050798832
148 rdf:type schema:CreativeWork
149 https://www.grid.ac/institutes/grid.20515.33 schema:alternateName University of Tsukuba
150 schema:name Department of Hematology, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan
151 Department of Pharmaceutical Sciences, University of Tsukuba, 1-1-1, Tennodai, 305-8575, Tsukuba, Ibaraki, Japan
152 rdf:type schema:Organization
153 https://www.grid.ac/institutes/grid.26999.3d schema:alternateName University of Tokyo
154 schema:name Division for Health Service Promotion, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan
155 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...